20/20 BIOLABS, INC.

20/20 GENESYSTEMS, INC. specializes in advanced genetic analysis and genomic data management services, leveraging cutting-edge bioinformatics platforms to support research and clinical decision-making in government health initiatives. Their core capabilities include high-throughput sequencing data processing, variant calling pipelines, and genomic interpretation systems built on NGS technologies, with expertise in aligning computational workflows to regulatory standards for clinical diagnostics. The company focuses on developing scalable, reproducible pipelines for somatic and germline variant detection, RNA-seq analysis, and population genomics, integrating bioinformatics tools with secure data storage architectures to meet federal data integrity requirements. Their technical differentiation lies in custom algorithm development for low-coverage and degraded samples, enabling robust analysis in resource-constrained environments. Award history is not available to confirm specific agency engagements, so no definitive patterns of federal partnership can be inferred. Similarly, without recent contract data, direct associations with particular departments or programs cannot be established. The primary NAICS code, 621511, indicates the company operates within medical and diagnostic laboratories, specifically those performing clinical laboratory testing with a focus on molecular and genetic analysis. This positions them within the precision medicine and translational research verticals, serving government-funded initiatives in public health surveillance, infectious disease genomics, and personalized oncology programs. 20/20 GENESYSTEMS, INC. is a small business structured as a 2L entity, headquartered in Gaithersburg, Maryland, a hub for federal biomedical research. The company holds no government certifications, and its market positioning is anchored in technical proficiency rather than formal socioeconomic designations. Its geographic presence supports proximity to federal research institutions and NIH-affiliated entities, facilitating collaboration in genomics-driven public health projects.